Collagenase Clostridium histolyticum (Xiapex®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000353
English
Authors' recommendations:
Collagenase Clostridium histolyticum (Xiapex®) is recommended as an option for restricted use within NHS Wales for the treatment of Dupuytren's contracture in adult patients with a palpable cord.
Collagenase Clostridium histolyticum (Xiapex®) should be restricted for use as an alternative to fasciectomy in a subset of adult patients with a total of two or less affected joints per hand where percutaneous needle fasciotomy is not appropriate, using up to three injections per cord, with no more than six injections per patient.
AWMSG is of the opinion that collagenase Clostridium histolyticum (Xiapex®) is not suitable for shared care within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=184836&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Microbial Collagenase
- Dupuytren Contracture
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.